{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:56:45Z","timestamp":1792195005793,"version":"4.4.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ekir.2017.11.017","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:02:41Z","timestamp":1511913761000},"page":"530-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Novel Therapies in Light Chain Amyloidosis"],"prefix":"10.1016","volume":"3","author":[{"given":"Paolo","family":"Milani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2017.11.017_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.11.017_bib2","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2017.11.017_bib4","doi-asserted-by":"crossref","first-page":"w13580","DOI":"10.4414\/smw.2012.13580","article-title":"AA amyloidosis: basic knowledge, unmet needs and future treatments","volume":"142","author":"Obici","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.ekir.2017.11.017_bib5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/ki.2013.558","article-title":"Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis","volume":"86","author":"Said","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.11.017_bib6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejim.2013.10.007","article-title":"Systemic amyloidoses: what an internist should know","volume":"24","author":"Palladini","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ekir.2017.11.017_bib7","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa013354","article-title":"Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis","volume":"346","author":"Lachmann","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.11.017_bib8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.5858\/2007-131-917-TOAIRB","article-title":"Typing of amyloidosis in renal biopsies: diagnostic pitfalls","volume":"131","author":"Satoskar","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ekir.2017.11.017_bib9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2011-06-358507","article-title":"Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients","volume":"119","author":"Sch\u00f6nland","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib10","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2014-11-609883","article-title":"A\u00a0practical approach to the diagnosis of systemic amyloidoses","volume":"125","author":"Fernandez de Larrea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib11","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib12","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1182\/blood-2011-07-365510","article-title":"Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue","volume":"119","author":"Brambilla","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5301\/jo-n.5000020","article-title":"Kidney involvement in light chain amyloidosis","volume":"1","author":"Milani","year":"2017","journal-title":"Journal of Onco-Nephrology"},{"key":"10.1016\/j.ekir.2017.11.017_bib14","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib15","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5301\/jo-n.5000005","article-title":"My patient with monoclonal gammopathy of undetermined significance has a kidney problem","volume":"1","author":"Leung","year":"2017","journal-title":"Journal of Onco-Nephrology"},{"key":"10.1016\/j.ekir.2017.11.017_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/labinvest.3700069","article-title":"Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns","volume":"84","author":"Teng","year":"2004","journal-title":"Lab Invest"},{"key":"10.1016\/j.ekir.2017.11.017_bib18","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/labinvest.3700161","article-title":"AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells","volume":"84","author":"Keeling","year":"2004","journal-title":"Lab Invest"},{"key":"10.1016\/j.ekir.2017.11.017_bib19","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.1365-2141.1999.01591.x","article-title":"Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis:association with dominant amyloid-related organ involvement and survival after stem cell transplantation","volume":"106","author":"Comenzo","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib20","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V98.3.714","article-title":"The tropism of organ involvement in primary systemic amyloidosis:contributions of Ig V(L) germ line gene use and clonal plasma cell burden","volume":"98","author":"Comenzo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2002-01-0114","article-title":"Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment","volume":"100","author":"Perfetti","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib22","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood-2002-09-2707","article-title":"Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL)","volume":"101","author":"Abraham","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","article-title":"The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1\u201344","volume":"119","author":"Perfetti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2016-10-743997","article-title":"Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry","volume":"129","author":"Kourelis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib26","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib27","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood-2015-11-681650","article-title":"Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis","volume":"127","author":"Weiss","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April. 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/978-94-007-5416-4_22","article-title":"The challenge of systemic immunoglobulin light-chain amyloidosis (Al)","volume":"65","author":"Palladini","year":"2012","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.ekir.2017.11.017_bib30","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","article-title":"Outcome in renal Al amyloidosis after chemotherapy","volume":"29","author":"Pinney","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2017.11.017_bib31","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2017.11.017_bib32","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2017.11.017_bib33","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2017.11.017_bib34","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.23141","article-title":"Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure","volume":"87","author":"Palladini","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib36","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2017.11.017_bib37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2017.11.017_bib38","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2017.11.017_bib39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib40","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/13506129.2013.854766","article-title":"Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone","volume":"21","author":"Bochtler","year":"2014","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2017.11.017_bib42","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2017.11.017_bib43","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","article-title":"Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study","volume":"128","author":"Bochtler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib44","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ekir.2017.11.017_bib45","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib46","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/asheducation.V2012.1.595.3798563","article-title":"Differential diagnosis of monoclonal gammopathy of undetermined significance","volume":"2012","author":"Merlini","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ekir.2017.11.017_bib48","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers:impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2017.11.017_bib49","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib50","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib51","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3324\/haematol.2012.079210","article-title":"A\u00a0detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?","volume":"98","author":"Leung","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2017.11.017_bib52","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ekir.2017.11.017_bib53","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2017.11.017_bib54","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib55","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2017.11.017_bib56","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib57","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2016.229","article-title":"Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis","volume":"31","author":"Landau","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ekir.2017.11.017_bib58","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ajh.24453","article-title":"Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation","volume":"91","author":"Hwa","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.22202","article-title":"Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis","volume":"87","author":"Irazabal","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib60","article-title":"HOVON 104; final results from a multicenter, prospective phase II study of bortezomib based induction treatment followed by autologous stem cell transplantation in patients with de novo al amyloidosis","volume":"102","author":"Minnema","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2017.11.017_bib61","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib62","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib63","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.11.017_bib64","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.12136","article-title":"Bortezomib in the treatment of AL amyloidosis: targeted therapy?","volume":"92","author":"Sitia","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2017.11.017_bib65","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib66","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2017.11.017_bib67","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","article-title":"Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib68","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib69","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2014-04-568329","article-title":"Long-term follow-up from a phase 1\/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis","volume":"124","author":"Reece","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib70","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib71","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib72","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib73","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients","volume":"28","author":"Palladini","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ekir.2017.11.017_bib74","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A\u00a0matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ekir.2017.11.017_bib75","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.V128.22.646.646","article-title":"A\u00a0randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib76","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1038\/bcj.2017.47","article-title":"Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib","volume":"7","author":"Kastritis","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ekir.2017.11.017_bib77","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/14779072.2015.1093936","article-title":"Novel strategies for the diagnosis and treatment of cardiac amyloidosis","volume":"13","author":"Palladini","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ekir.2017.11.017_bib78","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/ajh.24723","article-title":"Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis","volume":"92","author":"Tandon","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib79","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib80","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib81","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-011-1244-x","article-title":"Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide","volume":"91","author":"Palladini","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib82","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","article-title":"A\u00a0phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis","volume":"119","author":"Kastritis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib83","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","article-title":"Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis:long-term results from a phase 2 trial","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib84","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjh.12973","article-title":"Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens","volume":"166","author":"Mahmood","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib85","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfq482","article-title":"Kidney dysfunction during lenalidomide treatment for AL amyloidosis","volume":"26","author":"Specter","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.11.017_bib86","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood-2010-07-294405","article-title":"Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1\/2 dose-escalation study","volume":"116","author":"Moreau","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib87","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3324\/haematol.2012.075192","article-title":"Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial","volume":"98","author":"Sanchorawala","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2017.11.017_bib88","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bjh.13500","article-title":"A\u00a0phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis","volume":"170","author":"Cibeira","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib89","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3324\/haematol.2016.163246","article-title":"Lenalidomide\/melphalan\/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up","volume":"102","author":"Hegenbart","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2017.11.017_bib90","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib91","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib92","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A\u00a0phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib93","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib94","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A\u00a0phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib95","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib96","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1073\/pnas.92.7.2959","article-title":"Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis","volume":"92","author":"Merlini","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2017.11.017_bib97","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.V93.3.1112","article-title":"Treatment of AL amyloidosis with 4'-lodo-4'-deoxydoxorubicin:an update","volume":"93","author":"Merlini","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib98","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0002-9440(10)65065-1","article-title":"4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid","volume":"156","author":"Palha","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ekir.2017.11.017_bib99","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1096\/fj.02-0764com","article-title":"4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in\u00a0vitro producing noncytotoxic species:screening for TTR fibril disrupters","volume":"17","author":"Cardoso","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.ekir.2017.11.017_bib100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/13506120209072441","article-title":"A\u00a0multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL)","volume":"9","author":"Gertz","year":"2002","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2017.11.017_bib101","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.ekir.2017.11.017_bib102","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","article-title":"Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis","volume":"118","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib103","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A\u00a0Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis","volume":"123","author":"Diomede","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib104","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ekir.2017.11.017_bib105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/ars.2016.6848","article-title":"Cardiac light chain amyloidosis: the role of metal ions in oxidative stress and mitochondrial damage","volume":"27","author":"Diomede","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.ekir.2017.11.017_bib106","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.ekir.2017.11.017_bib107","doi-asserted-by":"crossref","first-page":"41515","DOI":"10.1038\/srep41515","article-title":"Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains","volume":"7","author":"Hora","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2017.11.017_bib108","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2007-05-089243","article-title":"Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?","volume":"110","author":"Hunstein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2017.11.017_bib109","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00392-010-0142-x","article-title":"Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis","volume":"99","author":"Mereles","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ekir.2017.11.017_bib110","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12185-016-2112-1","article-title":"Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis","volume":"105","author":"Meshitsuka","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib111","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","article-title":"Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis","volume":"417","author":"Pepys","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2017.11.017_bib112","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","article-title":"Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis","volume":"148","author":"Gillmore","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib113","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.11.017_bib114","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","article-title":"Antibody-mediated resolution of light chain-associated amyloid deposits","volume":"157","author":"Hrncic","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ekir.2017.11.017_bib115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/13506129.2017.1292900","article-title":"Interim analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11\u20131F4 in patients with AL amyloidosis","volume":"24","author":"Edwards","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2017.11.017_bib116","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","article-title":"2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis (\u2020)","volume":"23","author":"Renz","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2017.11.017_bib117","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II Study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2017.11.017_bib118","article-title":"Patients with light chain amyloidosis treated with NEOD001 achieve rapid organ responses that are independent of previous plasma cell-directed therapies","volume":"102","author":"Gertz","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2017.11.017_bib119","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/ajcn\/83.2.350","article-title":"Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis","volume":"83","author":"Caccialanza","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ekir.2017.11.017_bib120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00277-011-1309-x","article-title":"Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis","volume":"91","author":"Caccialanza","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ekir.2017.11.017_bib121","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/0148607113501328","article-title":"Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment","volume":"38","author":"Caccialanza","year":"2014","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.ekir.2017.11.017_bib122","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.nut.2015.04.011","article-title":"Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis","volume":"31","author":"Caccialanza","year":"2015","journal-title":"Nutrition"},{"key":"10.1016\/j.ekir.2017.11.017_bib123","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.1986.36","article-title":"Effect of dietary protein intake on albumin homeostasis in nephrotic patients","volume":"29","author":"Kaysen","year":"1986","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.11.017_bib124","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1527-5299.2003.01907.x","article-title":"Metolazone and its role in edema management","volume":"9","author":"Sica","year":"2003","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.ekir.2017.11.017_bib125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/heart.88.6.615","article-title":"Widespread cardiovascular autonomic dysfunction in primary amyloidosis:does spontaneous hyperventilation have a compensatory role against postural hypotension?","volume":"88","author":"Bernardi","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.ekir.2017.11.017_bib126","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917304539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917304539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:22:15Z","timestamp":1762831335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024917304539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S2468024917304539"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2017.11.017","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapies in Light Chain Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2017.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}